Home Immediapress Dragonfly Therapeutics Initiates Phase 1/1b Study of its IL-2 Immunotherapy in Patients with Advanced Solid Tumors
 

Immediapress

Dragonfly Therapeutics Initiates Phase 1/1b Study of its IL-2 Immunotherapy in Patients with Advanced Solid Tumors

 

(Adnkronos) - The company announces the first patient dosed in a Phase 1/1b clinical trial evaluating its novel IL-2 cytokine, DF6215, the seventh Dragonfly-developed drug to enter into clinical trials. WALTHAM, Mass., Dec. 5, 2023 /PRNewswire/ -- Drag

I contenuti di VeneziePost sono a pagamento.
Per visualizzare questo articolo e tutti i nostri contenuti scegli tra queste opzioni
Sei già iscritto a VeneziePost?
Clicca qui sotto e inserisci le tue credenziali
Accedi
Facebook Twitter Linkedin Email